June 5, 2017 / 3:32 PM / 2 months ago

BRIEF-Celldex presents data from phase 2 study of glembatumumab vedotin

1 Min Read

June 5 (Reuters) - Celldex Therapeutics Inc:

* Celldex presents promising overall survival data from phase 2 study of single-agent glembatumumab vedotin in patients with checkpoint-refractory metastatic melanoma

* Safety profile was consistent with prior studies of glembatumumab vedotin​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below